Zosano Pharma Corporation (NASDAQ:ZSAN) Q4 2019 Earnings Conference Call - Final Transcript

Mar 26, 2020 • 04:30 am ET

Previous

Zosano Pharma Corporation (NASDAQ:ZSAN) Q4 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Ladies and gentlemen, thank you for standing by and welcome to Zosano Corporate Update Conference Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Christine Matthews, Interim Chief Financial Officer. Please go ahead.

Executive
Christine Matthews

Thank you. Good afternoon and welcome to Zosano's conference call. We will be referring to an accompanying slide presentation entitled corporate presentation March 2020, which can be found on our website under the Investors tab, and within the Events and Presentations page. Joining me today with prepared remarks is Steven Lo, President and Chief Executive Officer. Later for the question-and-answer portion of the call we will also be joined by Don Kellerman, VP Clinical Development & Medical Affairs; Hayley Lewis, SVP of Operations; and Dushyant Pathak, SVP of Business Development.

Referring to Slide 2 of our corporate presentation, let me remind you that today's call may include forward-looking statements reflecting management's current expectations and beliefs. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially from those anticipated in such forward-looking statements. Forward-looking statements include but are not limited to our current expectations and projections relating to the anticipated progress of Qtrypta and C213 and the projected timelines for our research and development activities and other milestones, our ability to obtain FDA approval of Qtrypta and C213, our expectations regarding the relative benefits of our product candidates versus competitive therapies, our business partnering and capitalization strategy, our expectations regarding potential markets or market sizes, our expectations regarding the therapeutic and commercial potential of Qtrypta and C213 and our future financial results.

We assume no obligation to update or revise any forward-looking statements except as required by law. For a detailed description of the risks and uncertainties regarding our business, please refer to the Risk Factors section of our most recent Annual Report filed on Form 10-K and our periodic reports filed with the SEC.

With that I will now turn the call over to Steve Lo, our President and Chief Executive Officer, Steve?

Executive
Steven Lo

Thank you, Christine, and thank you all for joining us especially with everything that's going on in the world today. This is an exciting time for Zosano as we are in the rare and privileged position of being on the verge of becoming a commercial stage company. Our new drug application for Qtrypta, our product candidate for the acute treatment of migraine was accepted by the FDA earlier this month. And the PDUFA date for the completion of the FDA's review was set for October 20 of this year. Qtrypta has the potential to be an effective new therapeutic for patients with acute migraine. In our clinical program where we studied more than 6,000 migraine attacks, Qtrypta consistently demonstrated rapid and sustained headache relief with a favorable safety profile.

In brief, we believe Qtrypta has a highly competitive product profile. Given its potential to penetrate an important segment of the migraine market, we believe it could set us on